The goal of the study was to examine if the treatment remained effective in minimizing NAO symptoms due to nasal valve collapse two years later, after proving successful in three-month, six-month and one-year follow ups, according to a July 13 news release from Aerin Medical.
The findings revealed that the technology was successful in improving symptoms in 90.1 percent of patients after two years, corresponding to a 57 percent improvement overall.
VivAer is a stylus that is inserted into the nostril and uses patented, temperature-controlled radiofrequency energy to alter the nasal tissue and improve airflow.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
